About the Johns Hopkins Greenberg Bladder Cancer Institute

The Johns Hopkins Greenberg Bladder Cancer Institute was established in May 2014, thanks to a $15 million gift from Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife, Stephanie Cooper Greenberg, and a $30 million investment from the Johns Hopkins University.

The institute, the first of its kind in the world, is dedicated to advancing the scientific understanding of bladder cancer and improving its treatment. Our experts include multidisciplinary research teams from the Johns Hopkins Kimmel Cancer Center, as well as faculty from the Johns Hopkins University School of Medicine’s Department of Radiation Oncology and Molecular Radiation Sciences, the James Buchanan Brady Urological Institute at Johns Hopkins, and Johns Hopkins’ Departments of Pathology and Surgery.

Our scientists are leading novel research efforts in drug therapy and immunotherapy for bladder cancer; tissue engineering; and the study of biomarkers in urine to find new ways to diagnose and predict which patients will best respond to therapy. The institute also supports innovative research at other institutions through pilot research grants